

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CSPC PHARMACEUTICAL GROUP LIMITED

石藥集團有限公司

(Incorporated in Hong Kong under the Companies Ordinance)

(Stock Code: 1093)

TRADING HALT

At the request of CSPC Pharmaceutical Group Limited (the “Company”), trading in the Company’s shares on The Stock Exchange of Hong Kong Limited has been halted with effect from 9:00 a.m. on 21 November 2016 pending the release of an announcement containing inside information with regard to the receipt of government notice for suspension of production.

For and on behalf of the Board
CSPC Pharmaceutical Group Limited
CHAK Kin Man
Executive Director

Hong Kong, 21 November 2016

As at the date of this announcement, the board of directors of the Company comprises Mr. CAI Dongchen, Mr. CHAK Kin Man, Mr. PAN Weidong, Mr. WANG Shunlong, Mr. WANG Huaiyu, Mr. LU Jianmin, Mr. WANG Zhenguo, Mr. WANG Jinxu and Mr. LU Hua as executive directors; Mr. LEE Ka Sze, Carmelo as non-executive director; and Mr. CHAN Siu Keung, Leonard, Mr. WANG Bo, Mr. LO Yuk Lam, Mr. YU Jinming and Mr. CHEN Chuan as independent non-executive directors.